Letters Initial drug treatment in Parkinson’s disease

Authors’ reply to Braithwaite and Elrington

BMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h5846 (Published 03 November 2015) Cite this as: BMJ 2015;351:h5846
  1. Sharon Muzerengi, clinical research fellow neurology1,
  2. Carl E Clarke, professor of clinical neurology1
  1. 1School of Clinical and Experimental Medicine, College of Medicine and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK
  1. shammuzerengi{at}yahoo.com

In answer to Braithwaite, our recommendations were based on the National Institute for Health and Care Excellence (NICE) guidance on management of depression.1 2 3 We agree that reboxetine is not an effective treatment, as …

View Full Text

Log in

Log in through your institution


* For online subscription